HomeCompareCLVLF vs KO

CLVLF vs KO: Dividend Comparison 2026

CLVLF yields 0.39% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLF wins by $316.3K in total portfolio value· pulled ahead in Year 5
10 years
CLVLF
CLVLF
● Live price
0.39%
Share price
$8.45
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.4K
Annual income
$233,845.04
Full CLVLF calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — CLVLF vs KO

📍 CLVLF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLFKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLF + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLF pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLF
Annual income on $10K today (after 15% tax)
$32.77/yr
After 10yr DRIP, annual income (after tax)
$198,768.28/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, CLVLF beats the other by $195,110.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLF + KO for your $10,000?

CLVLF: 50%KO: 50%
100% KO50/50100% CLVLF
Portfolio after 10yr
$192.2K
Annual income
$119,074.41/yr
Blended yield
61.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

CLVLF
No analyst data
Altman Z
21.3
Piotroski
5/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLF buys
0
KO buys
0
No recent congressional trades found for CLVLF or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLFKO
Forward yield0.39%2.70%
Annual dividend / share$0.03$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%24.3%
Portfolio after 10y$350.4K$34.1K
Annual income after 10y$233,845.04$4,303.79
Total dividends collected$320.5K$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CLVLF vs KO ($10,000, DRIP)

YearCLVLF PortfolioCLVLF Income/yrKO PortfolioKO Income/yrGap
1$10,777$77.10$10,846$335.73$69.00KO
2$11,687$155.31$11,829$430.64$142.00KO
3$12,820$314.80$12,988$555.50$168.00KO
4$14,363$645.46$14,372$721.34$9.00KO
5← crossover$16,720$1,351.66$16,049$944.01+$671.00CLVLF
6$20,831$2,941.08$18,114$1,246.74+$2.7KCLVLF
7$29,138$6,849.18$20,702$1,664.24+$8.4KCLVLF
8$49,086$17,907.69$24,008$2,249.48+$25.1KCLVLF
9$108,908$56,386.61$28,317$3,085.19+$80.6KCLVLF
10$350,377$233,845.04$34,065$4,303.79+$316.3KCLVLF

CLVLF vs KO: Complete Analysis 2026

CLVLFStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLF Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this CLVLF vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLF vs SCHDCLVLF vs JEPICLVLF vs OCLVLF vs MAINCLVLF vs PEPCLVLF vs PGCLVLF vs JNJCLVLF vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.